The RealTime Dynamix™: Rheumatoid Arthritis report series provides a detailed and timely look at current and future trends in the RA market, and the effects of the future shifting landscape. Through a survey of 100 US rheumatologists, the 2016 Q2 installment does a deep dive into the influence and restrictions of managed care on biologic/JAK prescribing.
Rheumatologists are in tune with the reimbursement and access environment and actively involved in their
patients’ coverage and managed care issues.
Of the time, rheumatologists first check formulary coverage and co-pay information before starting RA patients on biologics/JAK agents
Just under two-thirds of rheumatologists report that they are involved with payers as it relates to the use of biologics/JAKs at least on a weekly basis.
Managed care influence and pressure for biologic/JAK prescription is high and has a significant
impact on treatment decisions.
Cost/insurance is the most selected barrier to increased use across all biologics/ Xeljanz, but use of Xeljanz, Actemra and Cimzia are perceived by rheumatologists as the most restricted by managed care.
Over half of all rheumatologists who believe that cost/reimbursement is a primary barrier for use of Xeljanz also think that plan coverage is the main issue.
Unaided, if cost/reimbursement were not an issue for Xeljanz,
Would use more
Would use Xeljanz first-line
prior after MTX failure
RealTime Dynamix: Rheumatoid Arthritis Q2 is the second installment of the 2016 report series focusing on current and anticipated future trends in the RA treatment landscape. For more information contact: [email protected]